慢性肢体威胁性缺血管理全球血管指南
慢性肢体威胁性缺血(CLTI)与死亡、截肢和生活质量受损相关。本全球血管指南聚焦CLTI的定义、评估和管理,推荐采用SVS WIfI分期和客观血流动力学检测,提出基于患者风险、肢体严重度和解剖复杂度的循证血运重建策略及GLASS分期系统。
要点
- CLTI定义为外周动脉疾病合并静息痛、坏疽或下肢溃疡>2周,排除静脉、创伤、栓塞及非动脉粥样硬化病因。
- 疑似CLTI患者应紧急转诊血管专科,采用WIfI系统分期,趾压为首选血流动力学检测。
- 循证血运重建基于患者风险、肢体严重度和解剖复杂度三轴,GLASS分期指导策略选择。
核心结论
- CLTI是临床综合征,需紧急转诊血管专科并规范评估。
- 推荐WIfI分期和客观血流动力学检测(趾压首选)评估肢体威胁程度。
- 循证血运重建基于患者风险、肢体严重度和解剖复杂度三轴决策。
- 所有CLTI患者应接受最佳药物治疗和长期肢体监测。
研究设计与样本
- 全球血管指南,由多学科专家制定,聚焦CLTI定义、评估和管理。
- 基于现有最佳证据提出推荐,待正在进行的试验提供1级证据。
主要发现
- CLTI与死亡、截肢和生活质量受损相关。
- CLTI定义为PAD合并静息痛、坏疽或下肢溃疡>2周。
- 静脉、创伤、栓塞和非动脉粥样硬化病因被排除。
- 非血运重建疗法(脊髓刺激、气压治疗、前列腺素类、高压氧)有效性未确立。
- 再生医学方法应限于严格随机临床试验。
关键数值与推荐
- CLTI定义:PAD合并静息痛、坏疽或下肢溃疡>2周。
- 推荐SVS WIfI系统基于伤口、缺血、足部感染分级进行分期。
- 趾压为CLTI首选的客观血流动力学检测指标。
- GLASS系统通过定义首选目标动脉路径(TAP)和基于肢体的通畅率(LBP)分为三个复杂度阶段。
- 平均风险和高风险患者由估计的手术和2年全因死亡率定义。
临床怎么用
- 疑似CLTI患者应紧急转诊血管专科。
- 采用WIfI系统分期评估肢体威胁严重度,并行趾压检测。
- 根据PLAN三轴(患者风险、肢体严重度、解剖复杂度)选择血运重建策略。
- 自体静脉可用时,平均风险、晚期肢体威胁和高复杂度病变可优选静脉旁路;解剖复杂度较低、肢体威胁中等或高风险患者可优选腔内治疗。
- 所有患者应接受抗血栓、降脂、降压、降糖治疗及戒烟、饮食、运动和足部护理咨询。
局限性
- 推荐基于现有最佳数据,待正在进行的试验提供1级证据。
- 非血运重建疗法的有效性尚未确立。
- 再生医学方法应限于严格随机临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic limb-threatening ischemia (CLTI) is associated with mortality, amputation, and impaired quality of life. These Global Vascular Guidelines (GVG) are focused on definition, evaluation, and management of CLTI with the goals of improving evidence-based care and highlighting critical research needs. The term CLTI is preferred over critical limb ischemia, as the latter implies threshold values of impaired perfusion rather than a continuum. CLTI is a clinical syndrome defined by the presence of peripheral artery disease (PAD) in combination with rest pain, gangrene, or a lower limb ulceration >2 weeks duration. Venous, traumatic, embolic, and nonatherosclerotic etiologies are excluded. All patients with suspected CLTI should be referred urgently to a vascular specialist. Accurately staging the severity of limb threat is fundamental, and the Society for Vascular Surgery Threatened Limb Classification system, based on grading of Wounds, Ischemia, and foot Infection (WIfI) is endorsed. Objective hemodynamic testing, including toe pressures as the preferred measure, is required to assess CLTI. Evidence-based revascularization (EBR) hinges on three independent axes: Patient risk, Limb severity, and ANatomic complexity (PLAN). Average-risk and high-risk patients are defined by estimated procedural and 2-year all-cause mortality. The GVG proposes a new Global Anatomic Staging System (GLASS), which involves defining a preferred target artery path (TAP) and then estimating limb-based patency (LBP), resulting in three stages of complexity for intervention. The optimal revascularization strategy is also influenced by the availability of autogenous vein for open bypass surgery. Recommendations for EBR are based on best available data, pending level 1 evidence from ongoing trials. Vein bypass may be preferred for average-risk patients with advanced limb threat and high complexity disease, while those with less complex anatomy, intermediate severity limb threat, or high patient risk may be favored for endovascular intervention. All patients with CLTI should be afforded best medical therapy including the use of antithrombotic, lipid-lowering, antihypertensive, and glycemic control agents, as well as counseling on smoking cessation, diet, exercise, and preventive foot care. Following EBR, long-term limb surveillance is advised. The effectiveness of nonrevascularization therapies (eg, spinal stimulation, pneumatic compression, prostanoids, and hyperbaric oxygen) has not been established. Regenerative medicine approaches (eg, cell, gene therapies) for CLTI should be restricted to rigorously conducted randomizsed clinical trials. The GVG promotes standardization of study designs and end points for clinical trials in CLTI. The importance of multidisciplinary teams and centers of excellence for amputation prevention is stressed as a key health system initiative.
引用
- Conte MS, Bradbury AW, Kolh P, et al. Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. Eur J Vasc Endovasc Surg. 2019. PMID: 31182334. doi:10.1016/j.ejvs.2019.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。